

# Tenosynovitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/TA3449B5A277EN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: TA3449B5A277EN

## Abstracts

The 7 major tenosynovitis markets are expected to exhibit a CAGR of 4.25% during 2024-2034.

The tenosynovitis market has been comprehensively analyzed in IMARC's new report titled "Tenosynovitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tenosynovitis refers to a medical condition characterized by the inflammation of the protective sheath surrounding a tendon, known as the synovium. Tendons are essential for connecting muscles to bones, facilitating movement. Inflammation of the synovium can lead to pain, swelling, and limited joint mobility. Common symptoms of tenosynovitis include localized tenderness, warmth, and stiffness in the affected area, often exacerbated by movement or pressure. The condition most commonly affects the fingers, wrists, hands, and feet, but it can occur in any tendon sheath throughout the body. Diagnosing this ailment typically involves a thorough medical history review and physical examination, focusing on the affected area's tenderness, swelling, and range of motion. Physicians may also utilize imaging techniques, like ultrasound or magnetic resonance imaging (MRI), to visualize the inflamed tendon sheath and rule out various other potential causes of the symptoms. Laboratory tests, such as blood workups, may further help to identify any underlying inflammatory conditions contributing to tenosynovitis.

The escalating cases of direct trauma or injury to a tendon due to sudden impact, twisting, or excessive force, resulting in inflammation of the synovium, are primarily driving the tenosynovitis market. In addition to this, the inflating utilization of effective treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, immobilization techniques, etc., to alleviate symptoms and hinder further

deterioration of the condition is creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapies, on account of their several benefits like enhancing muscle strength, refining coordination, and augmenting overall motor skills in individuals suffering from the illness, is also bolstering the market growth. Apart from this, the rising usage of minimally invasive procedures, such as ultrasound-guided tenosynovial debridement methods, since they aim at precisely addressing inflamed tendon sheaths and restoring joint function while reducing the risk of damaging adjacent structures, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine approaches, encompassing platelet-rich plasma (PRP) injections and stem cell therapies, which aid in tissue repair and alleviation of symptoms by harnessing the body's natural healing mechanisms, is expected to drive the tenosynovitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the tenosynovitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for tenosynovitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tenosynovitis market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the tenosynovitis market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the tenosynovitis market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current tenosynovitis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance  
Key Questions Answered in this Report:  
Market Insights

How has the tenosynovitis market performed so far and how will it perform in the coming years?  
What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the tenosynovitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the tenosynovitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of tenosynovitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of tenosynovitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of tenosynovitis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with tenosynovitis across the seven major markets?

What is the size of the tenosynovitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of tenosynovitis?

What will be the growth rate of patients across the seven major markets?

### Tenosynovitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for tenosynovitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tenosynovitis market?

What are the key regulatory events related to the tenosynovitis market?

What is the structure of clinical trial landscape by status related to the tenosynovitis market?

What is the structure of clinical trial landscape by phase related to the tenosynovitis market?

What is the structure of clinical trial landscape by route of administration related to the tenosynovitis market?

## Contents

?1 Preface

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 TENOSYNOVITIS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 TENOSYNOVITIS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 TENOSYNOVITIS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 TENOSYNOVITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 TENOSYNOVITIS - UNMET NEEDS**

## **10 TENOSYNOVITIS - KEY ENDPOINTS OF TREATMENT**

## **11 TENOSYNOVITIS - MARKETED PRODUCTS**

- 11.1 List of Tenosynovitis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 TENOSYNOVITIS - PIPELINE DRUGS**

### 12.1 List of Tenosynovitis Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13 TENOSYNOVITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14 TENOSYNOVITIS – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 TENOSYNOVITIS - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Tenosynovitis - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Tenosynovitis - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Tenosynovitis - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Tenosynovitis - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Tenosynovitis - Access and Reimbursement Overview

- 15.4 Market Scenario - Germany
  - 15.4.1 Tenosynovitis - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Tenosynovitis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Tenosynovitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Tenosynovitis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Tenosynovitis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Tenosynovitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Tenosynovitis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Tenosynovitis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Tenosynovitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Tenosynovitis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Tenosynovitis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Tenosynovitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Tenosynovitis - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Tenosynovitis - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Tenosynovitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Tenosynovitis - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Tenosynovitis - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Tenosynovitis - Access and Reimbursement Overview

## **16 TENOSYNOVITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 TENOSYNOVITIS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 TENOSYNOVITIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Tenosynovitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/TA3449B5A277EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TA3449B5A277EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

